Infectious Diseases (except HIV/AIDS)

Plant formulation ATRICOV 452 in improving the level of COVID-19 specific inflammatory markers in patients

1. Latha Damle
2. Hrishikesh Damle
3. Bharath BR

Reviewed by ScreenIT

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

1. Kimberly A Kraynyak
2. Elliott Blackwood
3. Joseph Agnes
4. Pablo Tebas
5. Mary Giffear
6. Dinah Amante
7. Emma L Reuschel
8. Mansi Purwar
9. Aaron Christensen-Quick
10. Neiman Liu
11. Viviane M Andrade
12. Malissa C Diehl
13. Snehal Wani
14. Martyna Lupicka
15. Albert Sylvester
16. Matthew P Morrow
17. Patrick Pezzoli
18. Trevor McMullan
19. Abhijeet J Kulkarni
20. Faraz I Zaidi
21. Drew Frase
22. Kevin Liaw
23. Trevor R F Smith
24. Stephanie J Ramos
25. John Ervin
26. Mark Adams
27. Jessica Lee
28. Michael Dallas
29. Ami Shah Brown
30. Jacqueline E Shea
31. J Joseph Kim
32. David B Weiner
33. Kate E Broderick
34. Laurent M Humeau
35. Jean D Boyer
36. Mammen P Mammen

Reviewed by ScreenIT

Nine-month presence of SARS-CoV-2 in saliva: a case report

1. Gijsbert J. Jansen
2. Marit Wiersma

Reviewed by ScreenIT

Covid-19 Vaccine Effectiveness in New York State

1. Eli S. Rosenberg
2. Vajeera Dorabawila
3. Delia Easton
4. Ursula E. Bauer
5. Jessica Kumar
6. Rebecca Hoen
7. Dina Hoefer
8. Meng Wu
9. Emily Lutterloh
10. Mary Beth Conroy
11. Danielle Greene
12. Howard A. Zucker

Reviewed by ScreenIT

COVIDNearTerm: A simple method to forecast COVID-19 hospitalizations

1. Adam B. Olshen
2. Ariadna Garcia
3. Kristopher I. Kapphahn
4. Yingjie Weng
5. Jason Vargo
6. John A. Pugliese
7. David Crow
8. Paul D. Wesson
9. George W. Rutherford
10. Mithat Gonen
11. Manisha Desai

Reviewed by ScreenIT

Analytical performance of eleven SARS-CoV-2 antigen-detecting rapid tests for Delta variant

1. Meriem Bekliz
2. Kenneth Adea
3. Manel Essaidi-Laziosi
4. Camille Escadafal
5. Jilian A Sacks
6. Laurent Kaiser
7. Isabella Eckerle

Reviewed by ScreenIT

Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers

1. Nasikarn Angkasekwinai
2. Jaturong Sewatanon
3. Suvimol Niyomnaitham
4. Supaporn Phumiamorn
5. Kasama Sukapirom
6. Sompong Sapsutthipas
7. Rujipas Sirijatuphat
8. Orasri Wittawatmongkol
9. Sansnee Senawong
10. Surakameth Mahasirimongkol
11. Sakalin Trisiriwanich
12. Kulkanya Chokephaibulkit

Reviewed by ScreenIT

4. Department of Mathematics and Statistics, Memorial University of Newfoundland, NL, Canada
5. Faculty of Medicine, Memorial University of Newfoundland, NL, Canada
6. Biology Department and Department of Mathematics and Statistics, Memorial University of Newfoundland, NL, Canada

Reviewed by ScreenIT

Fourteen-days Evolution of COVID-19 Symptoms During the Third Wave in Non-vaccinated Subjects and Effects of Hesperidin Therapy: A randomized, double-blinded, placebo-controlled study

1. Jocelyn Dupuis
2. Pierre Laurin
3. Jean-Claude Tardif
4. Leslie Hausermann
5. Camille Rosa
6. Marie-Claude Guertin
7. Karen Thibaudeau
8. Lyne Gagnon
9. Frank Cesari
10. Martin Robitaille
11. John E. Moran

Reviewed by ScreenIT

Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents

1. Beatriz Sánchez-Sendra
2. Eliseo Albert
3. Joao Zulaica
4. Ignacio Torres
5. Estela Giménez
6. Pilar Botija
7. María José Beltrán
8. Celia Rodado
9. Ron Geller
10. David Navarro

Reviewed by ScreenIT